Johnson & Johnson splits into two as big pharma downsizes
The company’s decision to split is likely being made so it can focus on its fast-growing pharmaceutical and medical device units.
By
The company’s decision to split is likely being made so it can focus on its fast-growing pharmaceutical and medical device units.
By MarketLineThe projected timeline for adopting digital medical services is becoming significantly shorter due to the impacts of Covid-19. Prior…
By MarketLineChinese drugmakers experience a 10% increase in share prices following a rising number of people infected by the coronavirus.…
By MarketLineThe main psychoactive component in magic mushrooms, psilocybin, has passed its first clinical safety trial. The drug is now…
By MarketLineDrug maker Novartis could become a leader in CVD therapeutics after purchasing The Medicine Company and its Atherosclerotic cardiovascular…
By MarketLine225 of the world’s largest corporations highlighted roughly $2.1 trillion of possible opportunities to capitalise on climate change, including…
By MarketLineDespite a small rally at the start of the year, the US biotech index still looks relatively cheap compared…
By MarketLineThe United States Department of Health and Human Services has proposed new limitations on pharmacy benefit manager rebates.
By MarketLineThe trial results raised concerns that the therapy will be unable to integrate enough corrective genetic material into the…
By MarketLineThank you for subscribing to Pharmaceutical Technology